This is the first of many urban centre clinics being launched as part of Canada House’s expansion plans
TORONTO, Feb. 21, 2019 — Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE:CHV) is pleased to announce the opening of its first Toronto clinic this Spring at the Champagne Centre, a multidisciplinary medical complex in North York. As a pioneer in cannabinoid therapy clinics, Canada House Clinics (CHC) is expanding to larger centres due to a significant and growing demand amongst key demographics including Boomers and Seniors, in addition to the Veterans
historically serviced by its clinics.
“Building on our special relationship with Veterans, Canada House is helping all Canadians who are serious about using medical cannabis to improve their health and well-being,” says Chris Churchill-Smith, CEO. “The Champagne Centre is ideal due to the large number of patients using the facility on a daily basis. We are extremely excited to have secured a lease there for our first Toronto clinic as we look to execute on Clinic expansion plans targeting larger urban centres throughout Canada.”
The Champagne Centre is an innovative 270,000 square foot health, sports, and wellness complex that includes the PolyClinic Family and Specialty Medicine Facility which has over 70 physicians and a wide range of diagnostic testing facilities. The strategic location will assist Canada House in extending its reach to new patients with specific health and wellness concerns.
In addition, a major hospital in North York recently announced its plans to open a large outpatient clinic in the Champagne Centre in 2019, adding to the 1,200 patients per day that visit the Champagne Centre.
“The philosophy of the Champagne Centre to create a quality health village with all specialties and services in one location resonates with the medical mission of Canada House Clinics,” says Alex Kroon, President Canada House Clinics. “We look forward to working with referring doctors in the Champagne Centre and across Toronto.”
Canada House is committed to working with the health system to secure coverage for medical cannabis patients by taking an evidence-based medical approach to responsible and effective cannabinoid therapy. CHC’s first Toronto clinic is yet another step in this direction, endeavoring to reach out to potential new users of medical cannabis.
For further information, please contact:
Boom Capital Markets
Canada House Wellness Group Inc.
Chris Churchill-Smith, CEO
ABOUT CANADA HOUSE WELLNESS GROUP INC.
Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy products and services through its clinics and licensed producer. Canada House is the parent company of Canada House Clinics Inc., Knalysis Technologies and Abba Medix Corp. For more information, please visit www.canadahouse.ca or www.sedar.com.
Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements.
Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.